{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Iwanaka T"],"funding":["KAKENHI","KAKENI"],"pagination":["134"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7093986"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["<h4>Background</h4>Human deciduous pulp stem cells (hDPSCs) have remarkable stem cell potency associated with cell proliferation, mesenchymal multipotency, and immunosuppressive function and have shown beneficial effects in a variety of animal disease models. Recent studies demonstrated that hDPSCs exhibited in vivo anti-fibrotic and anti-inflammatory action and in vivo hepatogenic-associated liver regeneration, suggesting that hDPSCs may offer a promising source with great clinical demand for treating liver diseases. However, how to manufacture ex vivo large-scale clinical-grade hDPSCs with the appropriate quality, safety, and preclinical efficacy assurances remains unclear.<h4>Methods</h4>We isolated hDPSCs from human deciduous dental pulp tissues formed by the colony-forming unit-fibrob"],"journal":["Stem cell research & therapy"],"pubmed_title":["A model study for the manufacture and validation of clinical-grade deciduous dental pulp stem cells for chronic liver fibrosis treatment."],"pmcid":["PMC7093986"],"funding_grant_id":["25293405","17K11513","18K08598","16H02682"],"pubmed_authors":["Matsuura T","Yamaza T","Sonoda S","Iwanaka T","Yoshimaru K","Oda Y","Yamaza H","Ohga S","Taguchi T"],"additional_accession":[]},"is_claimable":false,"name":"A model study for the manufacture and validation of clinical-grade deciduous dental pulp stem cells for chronic liver fibrosis treatment.","description":"<h4>Background</h4>Human deciduous pulp stem cells (hDPSCs) have remarkable stem cell potency associated with cell proliferation, mesenchymal multipotency, and immunosuppressive function and have shown beneficial effects in a variety of animal disease models. Recent studies demonstrated that hDPSCs exhibited in vivo anti-fibrotic and anti-inflammatory action and in vivo hepatogenic-associated liver regeneration, suggesting that hDPSCs may offer a promising source with great clinical demand for treating liver diseases. However, how to manufacture ex vivo large-scale clinical-grade hDPSCs with the appropriate quality, safety, and preclinical efficacy assurances remains unclear.<h4>Methods</h4>We isolated hDPSCs from human deciduous dental pulp tissues formed by the colony-forming unit-fibrob","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Mar","modification":"2025-04-18T11:51:18.572Z","creation":"2020-05-22T14:37:04Z"},"accession":"S-EPMC7093986","cross_references":{"pubmed":["32213198"],"doi":["10.1186/s13287-020-01630-w"]}}